Stifel analyst Rick Wise initiated coverage of Heartflow (HTFL) with a Buy rating and $35 price target The firm believes the company’s FFR CT and Plaque Analysis technology offers “meaningful value” for every coronary artery disease stakeholder. The company’s plaque analysis technology reimbursement in January should drive growth and potentially position plaque analysis software as an incremental growth driver for 2026 and beyond, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- Heartflow initiated with an Overweight at JPMorgan
- Heartflow initiated with an Overweight at Piper Sandler
- HeartFlow, Inc.: Innovative Technology and Strong Financial Performance Drive Buy Rating
- HeartFlow, Inc.: Positioned for Growth in AI-Powered Coronary Diagnostics with Strong Market Potential
- Innovative AI-Driven Diagnostics Propel HeartFlow, Inc. to Buy Rating